260 related articles for article (PubMed ID: 33974564)
1. Mesenchymal stromal cells reduce evidence of lung injury in patients with ARDS.
Wick KD; Leligdowicz A; Zhuo H; Ware LB; Matthay MA
JCI Insight; 2021 Jun; 6(12):. PubMed ID: 33974564
[TBL] [Abstract][Full Text] [Related]
2. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
Matthay MA; Calfee CS; Zhuo H; Thompson BT; Wilson JG; Levitt JE; Rogers AJ; Gotts JE; Wiener-Kronish JP; Bajwa EK; Donahoe MP; McVerry BJ; Ortiz LA; Exline M; Christman JW; Abbott J; Delucchi KL; Caballero L; McMillan M; McKenna DH; Liu KD
Lancet Respir Med; 2019 Feb; 7(2):154-162. PubMed ID: 30455077
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
[TBL] [Abstract][Full Text] [Related]
4. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study.
Zheng G; Huang L; Tong H; Shu Q; Hu Y; Ge M; Deng K; Zhang L; Zou B; Cheng B; Xu J
Respir Res; 2014 Apr; 15(1):39. PubMed ID: 24708472
[TBL] [Abstract][Full Text] [Related]
5. Markers of endothelial and epithelial pulmonary injury in mechanically ventilated COVID-19 ICU patients.
Spadaro S; Fogagnolo A; Campo G; Zucchetti O; Verri M; Ottaviani I; Tunstall T; Grasso S; Scaramuzzo V; Murgolo F; Marangoni E; Vieceli Dalla Sega F; Fortini F; Pavasini R; Rizzo P; Ferrari R; Papi A; Volta CA; Contoli M
Crit Care; 2021 Feb; 25(1):74. PubMed ID: 33608030
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.
Wilson JG; Liu KD; Zhuo H; Caballero L; McMillan M; Fang X; Cosgrove K; Vojnik R; Calfee CS; Lee JW; Rogers AJ; Levitt J; Wiener-Kronish J; Bajwa EK; Leavitt A; McKenna D; Thompson BT; Matthay MA
Lancet Respir Med; 2015 Jan; 3(1):24-32. PubMed ID: 25529339
[TBL] [Abstract][Full Text] [Related]
7. Investigational Use of Mesenchymal Stem/Stromal Cells and Their Secretome as Add-On Therapy in Severe Respiratory Virus Infections: Challenges and Perspectives.
Mattoli S; Schmidt M
Adv Ther; 2023 Jun; 40(6):2626-2692. PubMed ID: 37069355
[TBL] [Abstract][Full Text] [Related]
8. Umbilical Cord-derived Mesenchymal Stem Cells modulate TNF and soluble TNF Receptor 2 (sTNFR2) in COVID-19 ARDS patients.
Kouroupis D; Lanzoni G; Linetsky E; Messinger Cayetano S; Wishnek Metalonis S; Leñero C; Stone LD; Ruiz P; Correa D; Ricordi C
Eur Rev Med Pharmacol Sci; 2021 Jun; 25(12):4435-4438. PubMed ID: 34227081
[TBL] [Abstract][Full Text] [Related]
9. Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) Is Elevated in Bronchoalveolar Lavage Fluid of Patients with Acute Respiratory Distress Syndrome.
Attia EF; Jolley SE; Crothers K; Schnapp LM; Liles WC
PLoS One; 2016; 11(2):e0149687. PubMed ID: 26919714
[TBL] [Abstract][Full Text] [Related]
10. MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model.
Kaspi H; Semo J; Abramov N; Dekel C; Lindborg S; Kern R; Lebovits C; Aricha R
Stem Cell Res Ther; 2021 Jan; 12(1):72. PubMed ID: 33468250
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential.
Gorman E; Millar J; McAuley D; O'Kane C
Expert Rev Respir Med; 2021 Mar; 15(3):301-324. PubMed ID: 33172313
[No Abstract] [Full Text] [Related]
12. Intravenous Autologous Bone Marrow-derived Mesenchymal Stromal Cells Delay Acute Respiratory Distress Syndrome in Swine.
Batchinsky AI; Roberts TR; Antebi B; Necsoiu C; Choi JH; Herzig M; Cap AP; McDaniel JS; Rathbone CR; Chung KK; Cancio LC
Am J Respir Crit Care Med; 2023 Dec; 208(12):1283-1292. PubMed ID: 37797214
[No Abstract] [Full Text] [Related]
13. Mesenchymal stromal cells as treatment for acute respiratory distress syndrome. Case Reports following hematopoietic cell transplantation and a review.
Sadeghi B; Ringdén O; Gustafsson B; Castegren M
Front Immunol; 2022; 13():963445. PubMed ID: 36426365
[TBL] [Abstract][Full Text] [Related]
14. Safety, efficacy and biomarkers analysis of mesenchymal stromal cells therapy in ARDS: a systematic review and meta-analysis based on phase I and II RCTs.
Wang J; Luo F; Suo Y; Zheng Y; Chen K; You D; Liu Y
Stem Cell Res Ther; 2022 Jun; 13(1):275. PubMed ID: 35752865
[TBL] [Abstract][Full Text] [Related]
15. The evolution of radiographic edema in ARDS and its association with clinical outcomes: A prospective cohort study in adult patients.
Kotok D; Yang L; Evankovich JW; Bain W; Dunlap DG; Shah F; Zhang Y; Manatakis DV; Benos PV; Barbash IJ; Rapport SF; Lee JS; Morris A; McVerry BJ; Kitsios GD
J Crit Care; 2020 Apr; 56():222-228. PubMed ID: 32028223
[TBL] [Abstract][Full Text] [Related]
16. Inflammasome-regulated cytokines are critical mediators of acute lung injury.
Dolinay T; Kim YS; Howrylak J; Hunninghake GM; An CH; Fredenburgh L; Massaro AF; Rogers A; Gazourian L; Nakahira K; Haspel JA; Landazury R; Eppanapally S; Christie JD; Meyer NJ; Ware LB; Christiani DC; Ryter SW; Baron RM; Choi AM
Am J Respir Crit Care Med; 2012 Jun; 185(11):1225-34. PubMed ID: 22461369
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial.
Kaffash Farkhad N; Sedaghat A; Reihani H; Adhami Moghadam A; Bagheri Moghadam A; Khadem Ghaebi N; Khodadoust MA; Ganjali R; Tafreshian AR; Tavakol-Afshari J
Stem Cell Res Ther; 2022 Jun; 13(1):283. PubMed ID: 35765103
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome.
Ware LB; Koyama T; Zhao Z; Janz DR; Wickersham N; Bernard GR; May AK; Calfee CS; Matthay MA
Crit Care; 2013 Oct; 17(5):R253. PubMed ID: 24156650
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of mesenchymal stromal cell-derived therapies for acute respiratory distress syndrome-a meta-analysis of preclinical trials.
Wang F; Fang B; Qiang X; Shao J; Zhou L
Respir Res; 2020 Nov; 21(1):307. PubMed ID: 33218340
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS.
Häberle H; Magunia H; Lang P; Gloeckner H; Körner A; Koeppen M; Backchoul T; Malek N; Handgretinger R; Rosenberger P; Mirakaj V
J Intensive Care Med; 2021 Jun; 36(6):681-688. PubMed ID: 33663244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
